Targeting the C-MET/HGF Signaling Pathway in Pancreatic Ductal Adenocarcinoma

Title:Targeting the C-MET/HGF Signaling Pathway in Pancreatic Ductal Adenocarcinoma

Volume: 24 Issue: 39

Author(s): Sadaf Ghanaatgar-Kasbi, Shadi Khorrami, Amir Avan*, Seyed A. Aledavoud and Gordon A. Ferns*

Affiliation:

• Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad,Iran

• Brighton & Sussex Medical School, Division of Medical Education, Falmer, Brighton, Sussex BN1 9PH,United Kingdom

Keywords: c-mesenchymal-epithelial transition factor, HGF/Met inhibitors, pancreatic cancer, tumorigenesis, anti-tumor activity.

Abstract: The c-mesenchymal-epithelial transition factor (c-MET) is involved in the tumorigenesis of various cancers. HGF/Met inhibitors are now attracting considerable interest due to their anti-tumor activity in multiple malignancies such as pancreatic cancer. It is likely that within the next few years, HGF/Met inhibitors will become a crucial component for cancer management. In this review, we summarize the role of HGF/Met pathway in the pathogenesis of pancreatic cancer, with particular emphasize on HGF/Met inhibitors in the clinical setting, including Cabozantinib (XL184, BMS-907351), Crizotinib (PF-02341066), MK-2461, Merestinib (LY2801653), Tivantinib (ARQ197), SU11274, Onartuzumab (MetMab), Emibetuzumab (LY2875358), Ficlatuzumab (AV- 299), Rilotumumab (AMG 102), and NK4 in pancreatic cancer.

Cite this article as:

Ghanaatgar-Kasbi Sadaf , Khorrami Shadi , Avan Amir *, Aledavoud A. Seyed and Ferns A. Gordon*, Targeting the C-MET/HGF Signaling Pathway in Pancreatic Ductal Adenocarcinoma, Current Pharmaceutical Design 2018; 24 (39) . https://dx.doi.org/10.2174/1381612825666190110145855